Literature DB >> 7036817

Disopyramide.

F Morady, M M Scheinman, J Desai.   

Abstract

Since disopyramide was introduced 5 years ago, the therapeutic spectrum of this drug in treating patients with ventricular and atrial arrhythmias has been found to be similar to that of the other type I antiarrhythmic drugs, quinidine and procainamide. Disopyramide has the potential to suppress sinus node function and, therefore, must be used cautiously in patients with the sick sinus syndrome. The available data indicate that it can be used safely in patients with bundle branch block and first-degree or type I second-degree atrioventricular block. Disopyramide has been found at times to precipitate ventricular tachycardia or ventricular fibrillation. Because this drug often causes decompensation in patients with congestive heart failure, it must be used very cautiously, if at all, in such patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7036817     DOI: 10.7326/0003-4819-96-3-337

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  5 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Disopyramide and compromised ventricular function.

Authors:  K R Willis
Journal:  Can Med Assoc J       Date:  1983-02-15       Impact factor: 8.262

Review 3.  Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.

Authors:  Chiara Palandri; Lorenzo Santini; Alessia Argirò; Francesca Margara; Ruben Doste; Alfonso Bueno-Orovio; Iacopo Olivotto; Raffaele Coppini
Journal:  Drugs       Date:  2022-06-13       Impact factor: 11.431

4.  Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding.

Authors:  K Hanada; S Akimoto; K Mitsui; K Mihara; H Ogata
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

Review 5.  Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide.

Authors:  S Y Kim; N L Benowitz
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.